The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?
about
Facilitating the Validation of Novel Protein Biomarkers for Dementia: An Optimal Workflow for the Development of Sandwich ImmunoassaysThe potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's diseaseBiomarkers in dementia: clinical utility and new directionsIntroducing Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, an open access journal of the Alzheimer's AssociationOne-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond.Directional information flow in patients with Alzheimer's disease. A source-space resting-state MEG study.Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis.Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay.The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features.Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes.Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study.CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease.Cerebrospinal fluid ratios with Aβ42 predict preclinical brain β-amyloid accumulation.Increased CSF neurogranin concentration is specific to Alzheimer disease.Influence of APOE Genotype on Alzheimer's Disease CSF Biomarkers in a Spanish Population[(123)]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodiesDetection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers.The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.Random forest to differentiate dementia with Lewy bodies from Alzheimer's disease.The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease.A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology.Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South KoreaSubjective Cognitive Impairment Is a Predominantly Benign Condition in Memory Clinic Patients Followed for 6 Years: The Gothenburg-Oslo MCI StudyCerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disordersCerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.Cerebrospinal Fluid Levels of 14-3-3 Gamma: What Does It Tell Us About Sporadic Creutzfeldt-Jakob Disease?Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.Angelica sinensis reduced Aβ-induced memory impairment in rats.Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies.Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts.Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.Biomarkers for the Early Detection and Progression of Alzheimer's Disease.17q21.31 duplication causes prominent tau-related dementia with increased MAPT expression.Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis.Cerebrospinal Fluid Biomarkers in Alzheimer's Disease-From Brain Starch to Bench and Bedside.Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease.A neuroimaging approach to capture cognitive reserve: Application to Alzheimer's disease.Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: an MEG-based multiplex network study.
P2860
Q26781562-6AF5A7DD-CAA4-4696-AC32-C823C196608DQ26853347-1FDA0DF4-8648-4531-B8AA-5CA7A741BC10Q27007086-CFF6A8B3-2C04-4319-992B-DB8874BFA67BQ30489394-B2189A32-D176-466C-A37D-E65CE99D9999Q33808324-C0654B1C-C8E7-4C49-AFB3-C77448314A81Q33840101-CEFDCADA-C0F9-4234-A488-0488D334A3DCQ35750755-BF63B63D-5865-4069-B5A5-B4AE812B0CBBQ35857978-39ECF1E1-431F-4947-A57B-B89B870B2A7EQ36217479-DB0A96E5-F45B-4991-A9E1-15456EC30C78Q36404504-7688EDEB-49B0-41CF-842A-48B65D9F6EDAQ36454535-D963F17A-E9DF-40D8-BAE6-F0AA6C07B0DDQ36515507-7F358628-364B-4837-8E96-A2E50A4B55F5Q36639655-535B7031-BDAC-4AC0-BACC-3745566752AFQ36651546-B6350BBE-4745-474F-977A-5596C905344BQ36691986-3EB14790-B038-4425-B15C-778C122C52B5Q36764582-49A5F018-2C9B-4C27-988F-835D0251B099Q36834554-C82A3CD5-542D-497A-A58D-FBC89398074DQ36934163-67EF77E7-46C1-4D3D-A7CB-9C094A6482C2Q37169136-5EDE1F3D-6F52-4AEE-B40E-CEEF28DD95ABQ37310159-C068FBDD-4C52-4D9B-9D8D-881169EB4033Q37451440-ADD1EFD1-005E-45DE-8A16-8A837559129EQ37487835-87208FE1-F749-4222-B407-C8FFC0A489ABQ37648226-2349C7DF-4231-4B3B-B4EC-84A4ACF19BD2Q37665017-F0AB0077-761D-4E26-BA0E-E0AEC1CB00F5Q37695162-DB2F15E2-731A-408C-9E6A-582CBC6FC168Q37703133-AE8FF292-12A9-4CCF-8699-E5992BFB23A3Q38289739-A3BDF18F-5DB8-4EE4-8861-2E6EF34EC490Q38661989-D921B928-5957-4A8A-9339-E91AD9B27830Q38773523-39AAA133-EE1B-4CE3-B5E3-359FE9651B29Q38798611-B39D9BC3-FFBE-4E8F-B47A-2B305C824CA3Q38802883-E24C60F6-178A-4AC8-8EC0-4196AE6E6ABCQ38827967-2258E7F2-964F-41DB-B478-1A9C5417DEB1Q38853776-06F36EF2-CCCD-4EF6-BAAD-3E69396752F4Q38979999-44B52858-F5E8-405F-B184-6FA162A7BFF9Q39107119-324E5737-E27B-42E1-8C7C-B2F63F2BFD9AQ39342351-07F5EF67-6F1D-4FC1-878D-C0F519F43383Q39432592-E247E51A-395F-4240-9C42-9CF4732A5C4BQ39644582-62E34AB4-1F71-4737-BFDD-7E57E66B3517Q40153300-6A7369BB-4055-4E18-8712-B2BF7D774B51Q40277605-97821BDA-8F2F-43B0-8FF0-96A612CC8490
P2860
The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?
@en
The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?
@nl
type
label
The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?
@en
The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?
@nl
prefLabel
The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?
@en
The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?
@nl
P2093
P50
P1476
The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?
@en
P2093
Anders Wallin
Femke H Bouwman
Flora H Duits
Jan Marcusson
Johannes Schröder
Lucilla Parnetti
Marcel Olde Rikkert
Niels Andreasen
Pieter-Jelle Visser
P304
713-723.e2
P356
10.1016/J.JALZ.2013.12.023
P50
P577
2014-04-08T00:00:00Z